FEB 21, 2018 07:30 AM PST
Keynote Presentation: Evolving Paradigms of Pharmaco-MPE (Molecular Pathological Epidemiology) and Immuno-MPE for Precision Medicine
Presented at the Drug Discovery 2018 Virtual Event
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: CME | P.A.C.E. CE | Florida CE
1 1 71

Speakers:
  • Chief, Program in MPE Molecular Pathological Epidemiology, Brigham and Women's Hospital, Professor of Pathology and Epidemiology, Harvard Medical School, Dana-Farber Cancer Institute
    Biography
      Dr. Shuji Ogino is Professor (of Pathology and Epidemiology) at Dana-Farber Cancer Institute, Brigham and Women's Hospital (BWH), Harvard Medical School, and Harvard T.H. Chan School of Public Health; the founding Chief of Program in MPE Molecular Pathological Epidemiology at BWH; and an Associate Member of Broad Institute of MIT and Harvard. Dr. Ogino has been developing the transdisciplinary science "Molecular Pathological Epidemiology (MPE)", which bridges and integrates molecular biologic and population health sciences. Since 2013, he has been the Chairperson for The International MPE Meeting Series, and the Fourth International MPE Meeting will be held in Boston in 2018 (www.mpemeeting.org). Dr. Ogino has received numerous awards and honors, including CAP Foundation Scholars Award; USCAP Ramzi Cotran Young Investigator Award; Executive Officer's Award and Meritorious Service Award from AMP; recognitions of "Most Influential Scientific Minds" in 2014, and "Highly Cited Researcher" in 2015, 2016, and 2017 by Thomson Reuters and Clarivate Analytics; elected membership in ASCI; membership of FASEB Excellence in Science Award Committee; and membership of various NIH study sections, most notably NCI R35 Outstanding Investigator Award (OIA) Special Emphasis Panel in 2016. Dr. Ogino has been a recipient of prestigious NCI R35 OIA grant, which represent 7-year funding for me to pursue paradigm-shifting high impact research.

    Abstract:

    This lecture introduces the evolving paradigm of Molecular Pathological Epidemiology (MPE) as simply as possible.  Any given human disease represents fundamentally heterogeneous process, as implicated by the "unique disease principle".  MPE dissects complex interplay between environment, lifestyle factors, molecular pathogenic alterations, and disease occurrence and progression, using large populations.  MPE is a logical next step of genome-wide association studies (GWAS), termed “GWAS-MPE Approach”.  MPE has proven itself to be a promising approach to identify biomarkers for precision medicine (Chan A et al. NEJM 2007; Liao X et al. NEJM 2012; Nishihara R et al. NEJM 2013, etc.).  Recently, the "pharmaco-MPE" paradigm (Ogino S et al. npj Prec Oncol 2017) has been utilized to uncover effects of medications on health and diseases.  In addition, the "immuno-MPE" approach integrates immunology and MPE, to decipher effects of environment on immune status in health and diseases.  It is increasingly critical to design large-scale population-based MPE databases worldwide by means of integrating medication use, lifestyle factors, molecular pathology, immune status, and clinical outcome.  Such databases can generate novel information on potential chemopreventive or therapeutic benefits of drugs, which can be further tested by experimental models and clinical trials.  To expand opportunities and address challenges, the "International Molecular Pathological Epidemiology (MPE) Meeting Series" was established in 2013, and the Fourth International MPE Meeting will be held in Boston in 2018 (May 31 to June 1).  Because disease heterogeneity is a ubiquitous phenomenon, the MPE concept should be widespread to advance biomedical and population health sciences in the 21st century, and move us towards precision prevention and treatment. 


    Show Resources
    Loading Comments...